Dietary Advanced Glycation End-products and Insulin Resistance in Overweight and Obese Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00422253|
Recruitment Status : Completed
First Posted : January 15, 2007
Last Update Posted : December 16, 2013
We hypothesize that reduction in dietary advance glycation endproducts (AGE) intake will increase insulin sensitivity and normalise insulin secretion in overweight and obese individuals through reduction of chronic low grade inflammation.
We propose to test this hypothesis by performing euglycemic hypeinsulinemic glucose clamp and intravenous glucose tolerance test before and after low AGE diet and normal Australian diet in a cross-over design. This study will provide information relevant to the development and prevention of type 2 diabetes.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Insulin Resistance Obesity||Behavioral: dietary intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||27 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Will Reduction in Dietary Advanced Glycation End- Products Reduce Chronic Low Grade Inflammation and Improve Insulin Sensitivity in Overweight and Obese Humans|
|Study Start Date :||November 2006|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00422253
|Baker Heart Research Insitute|
|Melbourne, Victoria, Australia, 3186|
|Principal Investigator:||Barbora de Courten, MD PhD||Baker Heart Research Institute|